Up-regulation of the inflammatory-reparative phenotype in human prostate carcinoma

Prostate

Volumn 69, Issue 11, 2009, Pages 1245-1255

  Ravenna, Linda ^a,b   Sale, Patrizio ^c,d   Di Vito, Maura ^c   Russo, Andrea ^b   Salvatori, Luisa ^a,b,c   Tafani, Marco ^d   Mari, Emanuela ^c   Sentinelli, Steno ^b   Petrangeli, Elisa ^a,c   Gallucci, Michele ^b   Di Silverio, Franco ^c   Russo, Matteo A ^c,d  

^a CNR   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Estrogen receptors; Inflammatory and repair process; P2X7R; Prostate carcinoma; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; INDUCIBLE NITRIC OXIDE SYNTHASE; PENTRAXIN 3; PURINERGIC RECEPTOR; TRANSCRIPTION FACTOR RELA; C REACTIVE PROTEIN; DNA; EGFR PROTEIN, HUMAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PURINERGIC P2 RECEPTOR; PURINERGIC P2X7 RECEPTOR; RAGE PROTEIN, HUMAN; SERUM AMYLOID P; TUMOR ANTIGEN;

ARTICLE; CANCER GROWTH; CANCER TISSUE; CLINICAL ARTICLE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; INNATE IMMUNITY; LASER CAPTURE MICRODISSECTION; LEUKOCYTE; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; REAL TIME POLYMERASE CHAIN REACTION; TISSUE REPAIR; UPREGULATION; WESTERN BLOTTING; BIOPSY; CASE CONTROL STUDY; DNA REPAIR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION;

ANTIGENS, NEOPLASM; BIOPSY; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; DNA REPAIR; DNA, NEOPLASM; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; NITRIC OXIDE SYNTHASE TYPE II; PHENOTYPE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PURINERGIC P2; RNA, MESSENGER; SERUM AMYLOID P-COMPONENT; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 67650581533     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20966     Document Type: Article

References (28)

1. De MarzoAM,Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nature 2007;7:256-269.
2. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002;60:78-83.
3. Balkwill F, Coussens LM. An inflammatory link. Nature 2004; 431:405-406.
4. Karin M. Nuclear factor-kB in cancer development and progression. Nature 2006;441:431-436.
5. Oppenheim JJ, Yang D. Alarmins: Chemiotactic activators of immune responses. Curr Opin Immunol 2005;17:359-365.
6. Sabroe I, Parker LC, Dower SK, Whyte MK. The role of TLR activation in inflammation. J Pathol 2008;214:126-135.
7. Ramasamy R, Vannucci SJ, Du Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: A common thread in aging, diabetes, neurodegeneration and inflammation. Glycobiology 2005;15:16R-28R.
8. Lister MF, Sharkey J, Sawatzky DA, Hodgkiss JP, Davidson DJ, Rossi AG, Finlayson K. The role of the purinergic P2X7 receptor in inflammation. J Inflamm 2007;4:5.
9. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005;23: 337-366.
10. Curran EM, Judy BM, Duru NA, WangHQ, Vergara LA, Lubahn DB, EstesDM.Estrogenic regulation of host immunity against an estrogen receptor-negative human breast cancer. Clin Cancer Res 2006;12:5641-5647.
11. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005;64: 92-100.
12. Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 2003;191:125-135.
13. Wang J, Torbenson M, Wang Q, Ro JY, Becich M. Expression of inducible nitric oxide synthase in paired neoplastic and non-neoplastc primary prostate cell cultures and prostatectomy specimen. Urol Oncol 2003;21:117-122.
14. Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008;73:233-244.
15. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-3444.
16. Cheng J, Lee EJ, Madison LD, Lazennec G. Expression of estrogen receptor β in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett 2004; 566:169-172.
17. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, Risbridger GP. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB 2008;22:1512-1520.
18. Levin ER. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 2003; 17:309-317.
19. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10:331s-336s.
20. Imamov O, Morani A, Shim G-J, Omoto Y, Thulin-Andersson C, Warner M, Gustafsson JA. Estrogen receptor β regulates epithelial cellular differentiation in the mouse ventral prostate. Proc Natl Acad Sci 2004;101:9375-9380.
21. Walton TJ, Li G, Seth R, McArdle SE, Bishop MC, Rees RC.DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate 2008;68:210-222.
22. Dewan MZ, Ahmed S, Iwasaki Y, Ohba K, Toi M, Yamamoto N. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother 2006;60:273-276.
23. Sweeney C, Li L,ShanmugamR, Baht-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H, Cheng L. Nuclear Factor-kB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 2004; 10:5501-5507.
24. Lessard L, Bégin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localization of nuclear factor-kappaB transcription factors in prostate cancer: An immunohistochemical study. Br J Cancer 2005;93:1019-1023.
25. Chang JS, Wendt T,QuW, Kong L, Zou YS, SchmidtAM,Yan SF. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor of advanced glycation end products. Circ Res 2008;102:905-913.
26. 7 receptors into the plasma membrane of HEK293 cells. Toxicology 2007;238:60-69.
27. Yeh CH, Sturgis L, Haidacher J, Zhang XN, Sherwood SJ, Bjercke RJ, Juhasz O, Crow MT, Tilton RG, Denner L. Requirement for p38 and p44/p42 mitogen activated protein kinases in RAGE-mediated nuclear factor-kB transcriptional activation and cytokine secretion. Diabetes 2001;50:1495-1504.
28. Korcok J, RaimundoLN,KeHZ, Sims SM, Dixon SJ. Extracellular nucleotides act through P2X7 receptors to activate NF-κB in osteoclasts. J Bone Miner Res 2004;19:642-651.